Development asset linked to Taiho Pharma Canada in public FDA and regional records.
pharma · Myelodysplastic Syndromes (MDS) · Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML)
Taiho Pharma Canada
Taiho Pharma Netherlands B.V.
Taiho Pharma Canada drug portfolio — 30 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
2010 Winston Park Drive, Suite 503, Oakville, Ontario L6H 5R7, CA HQ
2017 Founded
13 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- 2010 Winston Park Drive, Suite 503, Oakville, Ontario L6H 5R7, CA
- Founded
- 2017
- Employees
- 13
- Programs
- 16
- Drugs
- 30
- Patents
- 0
Taiho Pharma Canada pipeline
Portfolio lens on 30 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Taiho Pharma Canada drug portfolio — 30 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
azacitidine
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA (cytosine-5)-methyltransferase 1.
- Target
- DNA (cytosine-5)-methyltransferase 1
- Mechanism
- DNA (cytosine-5)-methyltransferase 3A inhibitor
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
cedazuridine
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Cytidine deaminase.
- Target
- Cytidine deaminase
- Mechanism
- Cytidine deaminase inhibitor
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
decitabine
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA (cytosine-5)-methyltransferase 1.
- Target
- DNA (cytosine-5)-methyltransferase 1
- Mechanism
- DNA (cytosine-5)-methyltransferase 1 inhibitor
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- Thymidylate synthase inhibitor
-
fulvestrant
Antineoplastic and immunomodulating agents (L02)US regulatory status: approved. Molecular target: Estrogen receptor.
- Target
- Estrogen receptor
- Mechanism
- Estrogen receptor antagonist
-
futibatinib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Fibroblast growth factor receptor.
- Target
- Fibroblast growth factor receptor
- Mechanism
- Fibroblast growth factor receptor inhibitor
-
Development asset linked to Taiho Pharma Canada in public FDA and regional records. Mechanism: Mu opioid receptor agonist.
- Mechanism
- Mu opioid receptor agonist
-
Development asset linked to Taiho Pharma Canada in public FDA and regional records.
-
Development asset linked to Taiho Pharma Canada in public FDA and regional records.
-
US regulatory status: approved. Molecular target: DNA topoisomerase 1.
- Target
- DNA topoisomerase 1
- Mechanism
- DNA topoisomerase I inhibitor
-
Development asset linked to Taiho Pharma Canada in public FDA and regional records.
-
Development asset linked to Taiho Pharma Canada in public FDA and regional records.
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
pembrolizumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death protein 1.
- Target
- Programmed cell death protein 1
- Mechanism
- Programmed cell death protein 1 inhibitor
-
pemetrexed
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Dihydrofolate reductase.
- Target
- Dihydrofolate reductase
- Mechanism
- Thymidylate synthase inhibitor
-
US regulatory status: approved. Molecular target: Dihydrofolate reductase.
- Target
- Dihydrofolate reductase
- Mechanism
- Thymidylate synthase inhibitor
-
Development asset linked to Taiho Pharma Canada in public FDA and regional records.
-
Development asset linked to Taiho Pharma Canada in public FDA and regional records.
-
Development asset linked to Taiho Pharma Canada in public FDA and regional records.
-
Development asset linked to Taiho Pharma Canada in public FDA and regional records.
-
Development asset linked to Taiho Pharma Canada in public FDA and regional records.
-
Development asset linked to Taiho Pharma Canada in public FDA and regional records.
-
Development asset linked to Taiho Pharma Canada in public FDA and regional records.
-
Development asset linked to Taiho Pharma Canada in public FDA and regional records.
-
Development asset linked to Taiho Pharma Canada in public FDA and regional records.
-
venetoclax
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Apoptosis regulator Bcl-2.
- Target
- Apoptosis regulator Bcl-2
- Mechanism
- Apoptosis regulator Bcl-2 inhibitor